NEW YORK (GenomeWeb News) — PerkinElmer has extended by three years a deal with Schering-Plough to implement its OneSource technology at four of the drug maker’s labs in New Jersey.
 
The deal extends a previous instrument, service, and lab-management agreement between the two companies.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.